news5cleveland.com
Ohio weed costs double Michigan's, but lawmakers want to make it even more expensive
Ohio lawmakers are proposing limits on THC and higher taxes that could make cannabis less potent and more expensive. People with Crohn’s disease and other patients who rely on cannabis for symptom control could see reduced access, higher costs, or be pushed to alternative markets.
Ohio adults who use cannabis (medical or recreational); dispensary owners and employees; patients with IBD or Crohn’s using cannabis; clinicians and patient advocates following state cannabis policy.
What To Know
Why it matters This article reports on proposed Ohio legislation (Senate Bill 56) that would lower allowable THC in products, cap THC per edible package, raise sales tax on recreational cannabis, and limit home growing.
It includes a patient perspective: a dispensary owner with Crohn’s disease who says cannabis helped put him into remission and is concerned the changes could reduce access and raise prices. What to know The bill would cap THC content in edibles at 100 mg per package and reduce maximum THC concentration in adult-use extracts from 90% to 70%.
It would also raise the point-of-sale tax from 10% to 15% under the GOP proposal (the governor proposed 20%) and redirect tax revenue to the state General Revenue Fund rather than the specific funds created by Issue 2. The article includes local price comparisons (Ohio about $192/ounce vs.
Michigan about $84/ounce) and quotes industry and political figures describing motivations for the changes (consumer/child safety, government efficiency) and concerns about pushing consumers to the black market or to neighboring states.
Who should pay attention Adults who use medical or recreational cannabis in Ohio, dispensary owners and workers, patients (including people with Crohn’s disease) who use cannabis for symptom management, state clinicians advising patients on access, and advocates tracking cannabis policy.
More context This is reporting on state-level policy proposals and local perspectives, not clinical research. The article highlights potential impacts on price, potency, and home growing but does not provide clinical guidance or new medical evidence.
Readers interested in advocacy or access implications may want to follow official legislative updates for final bill language and enacted changes.
This is local news reporting on a proposed bill (S.B. 56) and stakeholder reactions. It quotes a patient-turned-dispensary-owner and lawmakers but does not present clinical trial data. Final law could change during the legislative process.
